Regeneron’s Eylea top choice for severe diabetes-related vision loss

February 18, 2015 10:03 PM

7 0

Regeneron Pharmaceuticals' top-selling eye drug, Eylea, bested Roche's Lucentis and Avastin in a U.S.-sponsored study in diabetes-related vision loss—though the results showed the effect was strongest in more severely affected patients.

The study, in 660 people with diabetic macular edema, showed Eylea was the most effective of the three medicines among patients who started the trial with vision of 20/50 or worse. Among patients starting with vision of 20/32 to 20/40, the medicines "showed no apparent differences," the study author...

Also watch: 'Still Reeling' Colbert Mourns the Loss of Bill O'Reilly With the Happiest Dance Imaginable

Read more

To category page